This Edition
ARTICLE | Product Development
Acrivon debuts with Lilly DDR inhibitor to test proteomics-based companion diagnostics platform
By Lauren Martz, Senior Editor
June 30, 2021 1:26 AM UTC
Access this Article
Request a Trial
Purchase This Article
Log in
BCIQ Company Profiles
Eli Lilly and Co.
Acrivon Therapeutics Inc.
BCIQ Company Profiles
Eli Lilly and Co.
Acrivon Therapeutics Inc.